



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2019





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

February 2019

N = 7384



Health Authority	Male	Female	All
FRASER	1432	422	1854
INTERIOR	404	100	504
NORTHERN	127	78	205
VANCOUVER COASTAL	3423	454	3877
VANCOUVER ISLAND	754	151	905
	6140	1205	7345
		Unknown/not stated:	39
		Total:	7384

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2014 - February 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2014 - February 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (February 2014 - February 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (February 2014 - February 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (February 2014 - February 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (February 2014 - February 2019)






1.8 Active and Inactive Participants
(February 2014 - February 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2014 - February 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2014 - February 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(February 2014 - February 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2014 - February 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2014 - February 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2014 - February 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(February 2014 - February 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2014 - February 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(February 2014 - February 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts
(February 2014 - February 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(February 2014 - February 2019)**






1.20 Cumulative Resistance Testing Results by Resistance Category (February 2014 - February 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2014 - February 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	5	900	5	<40	3
1988	28	7	0	7	7	530	7	<40	3
1989	26	55	1	56	46	460	56	<40	3
1990	24	56	1	57	51	500	57	<40	3
1991	25	38	3	41	32	570	41	<40	3
1992	24	64	5	69	52	565	66	<40	3
1993	23	137	16	153	142	575	149	<40	3
1994	22	83	13	96	76	553	91	<40	3
1995	22	133	23	156	127	530	149	<40	3
1996	20	357	54	411	343	590	389	<40	3
1997	18	291	32	323	289	650	309	<40	3
1998	17	197	45	242	205	560	227	<40	3
1999	17	167	40	207	182	600	198	<40	3
2000	18	129	33	162	144	575	157	<40	3
2001	17	128	32	160	132	575	154	<40	3
2002	16	126	27	153	121	600	144	<40	3
2003	15	159	29	188	157	620	181	<40	3
2004	14	165	37	202	167	600	194	<40	3
2005	13	192	46	238	200	630	224	<40	3
2006	12	195	40	235	193	600	223	<40	3
2007	11	256	51	307	256	600	285	<40	3
2008	10	297	72	369	310	650	347	<40	3
2009	10	324	69	393	321	660	371	<40	3
2010	8	282	72	354	297	630	335	<40	3
2011	8	339	73	412	358	680	392	<40	3
2012	7	280	63	343	288	710	323	<40	3
2013	6	277	67	344	285	650	328	<40	3
2014	5	292	53	345	271	710	324	<40	3
2015	4	300	48	348	301	650	333	<40	3
2016	3	288	58	346	292	650	317	<40	3
2017	2	247	39	286	247	640	271	<40	3
2018	1	240	52	292	250	570	286	<40	3
2019	0	51	10	61	55	510	60	71	3
Total:		6157	1204	7361					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7295	752	2386	<40	2106	610
FEB-2018	7257	764	1904	<40	1742	610
MAR-2018	7279	774	2050	<40	1827	617
APR-2018	7265	778	2082	<40	1841	620
MAY-2018	7288	780	2149	<40	1925	600
JUN-2018	7292	794	2008	<40	1791	610
JUL-2018	7298	793	2039	<40	1810	600
AUG-2018	7297	800	2093	<40	1874	618
SEP-2018	7251	804	2015	<40	1781	620
OCT-2018	7345	784	2170	<40	1931	610
NOV-2018	7352	789	2093	<40	1801	630
DEC-2018	7367	798	1750	<40	1511	620
JAN-2019	7403	800	2457	<40	2037	610
FEB-2019	7384	808	1854	<40	1498	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1417	3385	78	872	71	380
FEB-2018	1462	3149	79	1036	65	440
MAR-2018	1448	3242	75	59	70	485
APR-2018	1466	3175	71	808	62	484
MAY-2018	1449	3299	91	<40	82	455
JUN-2018	1457	3288	68	2980	64	440
JUL-2018	1460	3302	68	<40	53	570
AUG-2018	1495	3194	63	56	59	490
SEP-2018	1542	2990	88	220	81	410
OCT-2018	1470	3343	79	<50	68	360
NOV-2018	1475	3338	80	80	71	460
DEC-2018	1473	3353	54	359	43	450
JAN-2019	1465	3433	72	70	64	365
FEB-2019	1497	3328	74	83	63	560

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7253	1417	13	12	192	126	55	13218
FEB-2018	7221	1462	11	27	123	168	-32	13255
MAR-2018	7239	1448	17	21	152	134	18	13282
APR-2018	7231	1466	13	15	153	159	-8	13304
MAY-2018	7257	1449	9	12	170	144	26	13329
JUN-2018	7255	1457	13	16	148	150	-2	13351
JUL-2018	7254	1460	13	14	158	152	-1	13377
AUG-2018	7261	1495	9	27	155	162	7	13416
SEP-2018	7213	1542	16	15	154	194	-48	13442
OCT-2018	7311	1470	8	19	217	126	98	13478
NOV-2018	7327	1475	5	9	173	159	16	13504
DEC-2018	7343	1473	11	20	148	140	16	13530
JAN-2019	7377	1465	14	19	188	159	34	13564
FEB-2019	7361	1497	7	17	158	181	-16	13593

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	58	6730	451	55	7294	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	61	6686	451	59	7257	0.84%	92.13%	6.21%	0.81%	100.00%
MAR-2018	62	6708	454	56	7280	0.85%	92.14%	6.24%	0.77%	100.00%
APR-2018	58	6700	449	58	7265	0.80%	92.22%	6.18%	0.80%	100.00%
MAY-2018	64	6712	455	58	7289	0.88%	92.08%	6.24%	0.80%	100.00%
JUN-2018	61	6724	449	58	7292	0.84%	92.21%	6.16%	0.80%	100.00%
JUL-2018	53	6729	461	55	7298	0.73%	92.20%	6.32%	0.75%	100.00%
AUG-2018	54	6733	454	56	7297	0.74%	92.27%	6.22%	0.77%	100.00%
SEP-2018	51	6683	458	59	7251	0.70%	92.17%	6.32%	0.81%	100.00%
OCT-2018	53	6762	476	54	7345	0.72%	92.06%	6.48%	0.74%	100.00%
NOV-2018	53	6772	477	50	7352	0.72%	92.11%	6.49%	0.68%	100.00%
DEC-2018	51	6788	479	49	7367	0.69%	92.14%	6.50%	0.67%	100.00%
JAN-2019	52	6811	487	53	7403	0.70%	92.00%	6.58%	0.72%	100.00%
FEB-2019	53	6789	493	49	7384	0.72%	91.94%	6.68%	0.66%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3321 47%	9 32%	3077 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3636 51%
FEB-2018	13 35%	3322 47%	12 32%	3080 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3586 51%
MAR-2018	10 37%	3341 47%	10 37%	3105 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3567 50%
APR-2018	5 23%	3348 47%	5 23%	3116 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3540 50%
MAY-2018	9 39%	3356 47%	8 35%	3130 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3516 50%
JUN-2018	6 30%	3373 48%	6 30%	3149 45%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3485 49%
JUL-2018	7 28%	3401 48%	7 28%	3178 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3453 49%
AUG-2018	13 33%	3397 48%	14 36%	3185 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3418 48%
SEP-2018	4 15%	3380 48%	3 12%	3165 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3373 48%
OCT-2018	11 31%	3423 48%	9 26%	3209 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3384 47%
NOV-2018	9 35%	3433 48%	8 31%	3219 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	492 7%	17 65%	3356 47%
DEC-2018	8 31%	3449 48%	8 31%	3236 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	16 62%	3355 47%
JAN-2019	8 24%	3475 48%	7 21%	3261 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	25 74%	3364 47%
FEB-2019	13 45%	3467 48%	12 41%	3265 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	544 8%	13 45%	3310 46%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3712	52%
FEB-2018	24	65%	3680	52%
MAR-2018	17	63%	3673	52%
APR-2018	17	77%	3662	52%
MAY-2018	14	61%	3662	52%
JUN-2018	14	70%	3662	52%
JUL-2018	18	72%	3655	52%
AUG-2018	25	64%	3651	52%
SEP-2018	22	85%	3633	52%
OCT-2018	24	69%	3685	52%
NOV-2018	17	65%	3673	51%
DEC-2018	18	69%	3676	51%
JAN-2019	26	76%	3703	51%
FEB-2019	16	55%	3680	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	196 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1258 44%	15 100%	1422 49%	0 0%	190 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1247 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1223 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1210 43%	5 100%	1443 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1434 51%	0 0%	177 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1171 42%	7 70%	1443 52%	1 10%	170 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1157 42%	11 69%	1426 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1134 42%	6 86%	1409 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1123 41%	15 83%	1450 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1462 54%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1464 54%	1 11%	145 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1101 40%	11 92%	1481 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1073 40%	9 82%	1477 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	707 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	697 36%	0 0%	234 12%	0 0%	710 36%	2 40%	324 17%
NOV-2018	8 80%	688 35%	0 0%	230 12%	0 0%	700 36%	2 20%	323 17%
DEC-2018	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	320 17%
JAN-2019	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	319 17%
FEB-2019	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	312 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2007 60%	8 42%	632 19%	0 0%	46 1%	2 11%	688 21%
FEB-2018	0 0%	0 0%	16 70%	2028 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%
MAR-2018	0 0%	0 0%	14 100%	2062 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2107 61%	4 33%	654 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2140 61%	4 20%	665 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	7 64%	2174 62%	3 27%	675 19%	0 0%	42 1%	1 9%	678 19%
JUL-2018	0 0%	0 0%	7 58%	2210 62%	4 33%	676 19%	0 0%	43 1%	1 8%	677 19%
AUG-2018	0 0%	0 0%	23 79%	2255 62%	5 17%	676 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	690 19%	0 0%	41 1%	0 0%	656 18%
OCT-2018	0 0%	17 0%	13 76%	2320 63%	4 24%	708 19%	0 0%	40 1%	0 0%	659 18%
NOV-2018	0 0%	17 0%	11 100%	2346 63%	0 0%	705 19%	0 0%	38 1%	0 0%	651 17%
DEC-2018	0 0%	17 0%	13 72%	2369 63%	5 28%	721 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 79%	2431 63%	3 16%	732 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2441 63%	5 23%	726 19%	0 0%	40 1%	1 5%	653 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2010	27.56	1645	22.55	2596	35.59	117	1.60	55	0.75	871	11.94
FEB-2018	1968	27.12	1630	22.46	2616	36.05	116	1.60	59	0.81	868	11.96
MAR-2018	1978	27.17	1616	22.20	2648	36.37	113	1.55	56	0.77	869	11.94
APR-2018	1937	26.66	1596	21.97	2699	37.15	114	1.57	58	0.80	861	11.85
MAY-2018	1931	26.49	1575	21.61	2739	37.58	114	1.56	58	0.80	872	11.96
JUN-2018	1911	26.21	1564	21.45	2790	38.26	113	1.55	58	0.80	856	11.74
JUL-2018	1887	25.86	1567	21.47	2820	38.64	110	1.51	55	0.75	859	11.77
AUG-2018	1866	25.57	1549	21.23	2864	39.25	111	1.52	56	0.77	851	11.66
SEP-2018	1830	25.24	1533	21.14	2878	39.69	109	1.50	59	0.81	842	11.61
OCT-2018	1852	25.21	1529	20.82	2947	40.12	104	1.42	54	0.74	859	11.70
NOV-2018	1846	25.11	1524	20.73	2969	40.38	106	1.44	50	0.68	857	11.66
DEC-2018	1840	24.98	1511	20.51	3007	40.82	104	1.41	49	0.67	856	11.62
JAN-2019	1838	24.83	1482	20.02	3064	41.39	100	1.35	53	0.72	866	11.70
FEB-2019	1807	24.47	1478	20.02	3082	41.74	99	1.34	49	0.66	869	11.77

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	14	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	20	2	0	5	5	8	433
JAN-2019	19	3	3	2	4	5	380
FEB-2019	17	1	0	6	4	4	400

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11961	3656
FEB-2018	11991	3671
MAR-2018	12019	3700
APR-2018	12051	3731
MAY-2018	12086	3756
JUN-2018	12098	3759
JUL-2018	12124	3783
AUG-2018	12138	3778
SEP-2018	12161	3799
OCT-2018	12181	3800
NOV-2018	12219	3820
DEC-2018	12223	3814
JAN-2019	12265	3842
FEB-2019	12278	3846

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
February 2019

N = 7384

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	12	14	*
	50+	25	36	*
	Total HSDA:	42	55	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	69	92	51	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	368	491	280	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	41
	50+	*	*	89
Total HSDA:	189	252	144	
Total HA:		668	890	504

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		668	890	504

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	530	710	404
Female	138	180	100

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	504	54	590	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	10
	5 years or more	8	6
	<5 years	16	13
	Total HSDA:	42	29
KOOTENAY BOUNDARY	10 years or more	44	32
	5 years or more	12	10
	<5 years	13	9
	Total HSDA:	69	51
OKANAGAN	10 years or more	226	163
	5 years or more	65	54
	<5 years	77	63
	Total HSDA:	368	280
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	106	75
	5 years or more	39	33
	<5 years	44	36
	Total HSDA:	189	144
Total HA:		668	504

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	394	280
5 years or more	124	103
<5 years	150	121
Total HA:	668	504

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	40	58	12	24
KOOTENAY BOUNDARY	68	119	21	43
OKANAGAN	210	910	61	284
THOMPSON/CARIBOO/SHUSWAP	128	491	37	135
Total:	446	1578	131	486

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	96

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		364	450
FRASER NORTH	0-19	10	10	*
	20-34	109	111	*
	35-49	350	384	*
	50+	531	847	*
	Total HSDA:		1000	1352
FRASER SOUTH	0-19	7	7	*
	20-34	117	119	*
	35-49	340	387	*
	50+	516	761	*
	Total HSDA:		980	1274
Total HA:		2344	3076	1854

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	21	21	9
	20-34	256	262	180
	35-49	801	893	635
	50+	1266	1900	1030
Total HA:		2344	3076	1854

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1781	2360	1432
Female	563	716	422

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1854	51	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	203	153
	5 years or more	87	70
	<5 years	74	58
	Total HSDA:	364	281
FRASER NORTH	10 years or more	536	385
	5 years or more	249	200
	<5 years	215	182
	Total HSDA:	1000	767
FRASER SOUTH	10 years or more	510	413
	5 years or more	229	183
	<5 years	241	210
	Total HSDA:	980	806
Total HA:		2344	1854

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1249	951
	5 years or more	565	453
	<5 years	530	450
Total HA:		2344	1854

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	138	487	36	68
FRASER NORTH	246	1540	52	243
FRASER SOUTH	211	1331	46	368
Total:	595	3358	134	679

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	196
FRASER NORTH	650
FRASER SOUTH	551
Total:	1397

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	64
	50+	*	*	197
	Total HSDA:		332	478
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		168	217
VANCOUVER	0-19	34	36	6
	20-34	437	449	321
	35-49	1430	1608	1049
	50+	2750	4677	2087
	Total HSDA:	4651	6770	3463
Total HA:		5151	7465	3877

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	37	39	7
	20-34	487	500	359
	35-49	1555	1746	1149
	50+	3072	5180	2362
Total HA:		5151	7465	3877

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4532	6548	3423
Female	617	915	454

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3877	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	181	148
	5 years or more	82	71
	<5 years	69	62
	Total HSDA:	332	281
RICHMOND	10 years or more	90	66
	5 years or more	40	34
	<5 years	38	33
	Total HSDA:	168	133
VANCOUVER	10 years or more	2636	1890
	5 years or more	1203	893
	<5 years	812	680
	Never on ART	0	0
	Total HSDA:	4651	3463
Total HA:	5151	3877	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2907	2104
5 years or more	1325	998
<5 years	919	775
Never on ART	0	0
Total HA:	5151	3877

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	166	486	51	173
RICHMOND	43	284	11	93
VANCOUVER	587	10705	193	5373
Total:	796	11475	255	5639

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	113

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		309	439
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		121	161
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		720	1016
Total HA:		1150	1616	905

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	99	105	*
	35-49	308	357	*
	50+	737	1148	*
Total HA:		1150	1616	905

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	948	1331	754
Female	202	285	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	905	54	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	168	141
	5 years or more	70	61
	<5 years	71	56
	Total HSDA:	309	258
NORTH VANCOUVER ISLAND	10 years or more	68	59
	5 years or more	29	22
	<5 years	24	19
	Total HSDA:	121	100
SOUTH VANCOUVER ISLAND	10 years or more	410	293
	5 years or more	153	124
	<5 years	157	130
	Total HSDA:	720	547
Total HA:		1150	905

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	646	493
5 years or more	252	207
<5 years	252	205
Total HA:	1150	905

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	836	75	190
NORTH VANCOUVER ISLAND	132	260	47	74
SOUTH VANCOUVER ISLAND	209	1749	45	556
Total:	532	2845	167	820

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	48
NORTH VANCOUVER ISLAND	36
SOUTH VANCOUVER ISLAND	105
Total:	189

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	10
	35-49	*	*	16
	50+	*	*	28
	Total HSDA:		71	109
NORTHERN INTERIOR	0-19	6	6	*
	20-34	18	20	*
	35-49	70	87	*
	50+	85	142	*
	Total HSDA:		179	255
Total HA:		289	411	205

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	8	8	*
	20-34	32	36	*
	35-49	108	144	*
	50+	141	223	*
Total HA:		289	411	205

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	176	254	127
Female	113	157	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	205	50	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	8
	5 years or more	14	7
	<5 years	8	5
	Total HSDA:	39	20
NORTH WEST	10 years or more	32	20
	5 years or more	25	21
	<5 years	14	13
	Total HSDA:	71	54
NORTHERN INTERIOR	10 years or more	71	51
	5 years or more	62	50
	<5 years	46	30
	Total HSDA:	179	131
Total HA:		289	205

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	120	79
5 years or more	101	78
<5 years	68	48
Total HA:	289	205

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	61	6	6
NORTH WEST	70	160	13	29
NORTHERN INTERIOR	103	448	15	177
Total:	211	669	34	212

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	19
NORTHERN INTERIOR	14
Total:	39

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	21	36	13
	THOMPSON/CARIBOO/SHUSWAP	27	45	19
	Total HA:	60	100	43
FRASER	FRASER EAST	42	52	33
	FRASER NORTH	53	89	45
	FRASER SOUTH	71	104	53
	Total HA:	166	245	131
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	12	17	9
	VANCOUVER	498	850	402
	Total HA:	535	915	435
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	78	40
	NORTH VANCOUVER ISLAND	15	24	13
	SOUTH VANCOUVER ISLAND	35	77	24
	Total HA:	100	179	77
NORTHERN	NORTH EAST	10	12	7
	NORTH WEST	33	62	26
	NORTHERN INTERIOR	63	100	47
	Total HA:	106	174	80
Total:		967	1613	766

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	603	1028	479
Female	364	585	287

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	766	51	500	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

